UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis

[1]  P. Royston,et al.  Combined test versus logrank/Cox test in 50 randomised trials , 2019, Trials.

[2]  Eric A. Miller,et al.  Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. , 2019, The lancet. Gastroenterology & hepatology.

[3]  T. Church,et al.  Long-Term Effectiveness of Sigmoidoscopy Screening in Women and Men , 2018, Annals of Internal Medicine.

[4]  M. Bretthauer,et al.  Long-Term Effectiveness of Sigmoidoscopy Screening in Women and Men , 2018, Annals of Internal Medicine.

[5]  Eric A. Miller,et al.  Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial , 2018, BJU international.

[6]  J. Hanley,et al.  Disaggregating the mortality reductions due to cancer screening: model-based estimates from population-based data , 2018, European Journal of Epidemiology.

[7]  M. Vatn,et al.  Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men , 2018, Annals of Internal Medicine.

[8]  P. Royston.  Power and sample-size analysis for the Royston–Parmar combined test in clinical trials with a time-to-event outcome , 2018 .

[9]  I. Kralj-Hans,et al.  Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial , 2017, The Lancet.

[10]  J. Gohagan,et al.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.

[11]  J. Gohagan,et al.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. , 2016, Gynecologic oncology.

[12]  T. Karrison.  Versatile Tests for Comparing Survival Curves Based on Weighted Log-rank Statistics , 2016 .

[13]  M. Parmar,et al.  Abstract CT104: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial , 2016 .

[14]  D. Oram,et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.

[15]  Patrick Royston,et al.  Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated , 2016, BMC Medical Research Methodology.

[16]  S. Duffy,et al.  Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. , 2015, The Lancet. Oncology.

[17]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[18]  M. Hernán,et al.  Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. , 2014, JAMA.

[19]  P. Royston,et al.  An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect , 2014, Trials.

[20]  Ruth Etzioni,et al.  What do the screening trials really tell us and where do we go from here? , 2014, The Urologic clinics of North America.

[21]  T. To,et al.  Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial , 2014, BMJ : British Medical Journal.

[22]  J. Hanley,et al.  Measuring the Mortality Impact of Breast Cancer Screening , 2013, Canadian Journal of Public Health.

[23]  Mark P Purdue,et al.  Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. , 2012, The New England journal of medicine.

[24]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[25]  L. Bisanti,et al.  Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. , 2011, Journal of the National Cancer Institute.

[26]  L. Tabár,et al.  Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. , 2011, Radiology.

[27]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[28]  J. Hanley.  Measuring mortality reductions in cancer screening trials. , 2011, Epidemiologic reviews.

[29]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[30]  O. Löfman,et al.  Randomised prostate cancer screening trial: 20 year follow-up , 2011, BMJ : British Medical Journal.

[31]  David A Lynch,et al.  Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. , 2010, Journal of the National Cancer Institute.

[32]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[33]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[34]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[35]  M. Parmar,et al.  Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study , 2008, BMJ : British Medical Journal.

[36]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[37]  Graeme W Morgan,et al.  Reduction in mortality from breast cancer , 2005, BMJ : British Medical Journal.

[38]  O. Löfman,et al.  Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. , 2004, European urology.

[39]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.

[40]  A. Miller,et al.  Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. , 2000, Journal of the National Cancer Institute.

[41]  L. Tabár,et al.  The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. , 2000, Radiologic clinics of North America.

[42]  W. Hepburn,et al.  14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening , 1999, The Lancet.

[43]  S. Duffy,et al.  The Gothenburg breast screening trial , 1998, Cancer.

[44]  S. Duffy,et al.  The Gothenburg Breast Screening Trial , 1997, Cancer.

[45]  C J Baines,et al.  The Gothenburg breast screening trial , 1997, Cancer.

[46]  L. Rutqvist,et al.  Followup after 11 years – update of mortality results in the Stockholm mammographic screening trial , 1997, Breast Cancer Research and Treatment.

[47]  G. Eklund,et al.  Randomized study of mammography screening — preliminary report on mortality in the stockholm trial , 1991, Breast Cancer Research and Treatment.

[48]  T. Landberg,et al.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. , 1988, BMJ.

[49]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[50]  J. Dungan.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2012 .

[51]  M. Roizen.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[52]  Matthew Burnell,et al.  Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. , 2011, The Lancet. Oncology.

[53]  G. Eklund,et al.  The Stockholm breast cancer screening trial — 5-year results and stage at discovery , 2005, Breast Cancer Research and Treatment.

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[55]  C J Baines,et al.  The Canadian National Breast Screening Study: update on breast cancer mortality. , 1997, Journal of the National Cancer Institute. Monographs.